Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
10 Results for "
YTHDC1
" in MedChemExpress (MCE) Product Catalog:
Products (10)
10 Results for "YTHDC1" in MCE Product Catalog:
Cat. No.: HY-164607
CAS No.: 3056857-07-6
Target:
Research Areas:
YL-5092 is a selective YT521-B homology (YTH) domain-containing protein 1 (YTHDC1) inhibitor with an IC50 of 7.4 nM and a KD of 29.6 nM. YL-5092 can suppress cancer cell proliferation and induce cell G0/G1 phase arrest and apoptosis. YL-5092 can be used for the research of cancer, such as acute myeloid leukemia (AML) [1].
Target:
Research Areas:
YTHDC1-IN-1 is a selective YTHDC1 inhibitor with a Kd of 49 nM and an IC50 of 0.35 μM. YTHDC1-IN-1 can inhibit the proliferation and induce apoptosis of acute myeloid leukemia cell lines. YTHDC1-IN-1 has anti-tumor activity [1].
Cat. No.: HY-174982
CAS No.: 3093182-34-1
YTHDF2 ligand-1 (Compound 23) is a competitive, selective, and high-affinity YTHDF2 ligand with an IC50 of 11 μM and a Kd of 1.3 μM. YTHDF2 ligand-1 competes with m 6A-RNA for binding to YTHDF2. YTHDF2 ligand-1 is applicable for cancer research [1].
Cat. No.: HY-168610
CAS No.: 2189366-92-3
Target:
Research Areas:
YTH-IN-1 (compound N-7) is a pan-YTH domain inhibitor with the IC50 values of 39 μM, 34 μM, 35 μM, 48 μM and 30 μM for human YTH YTHDF1, YTH YTHDF2, YTH YTHDF3, YTH YTHDC1, and YTH YTHDC2, respectively [1].
Cat. No.: HY-173008
YTHDF2-IN-1 (Compound CK-75) is a selective YTHDF2 inhibitor (Kd = 26.2 μM). YTHDF2-IN-1 binds to a small hydrophobic pocket on the YTH domain of YTHDF2, disrupting the interaction between YTHDF2 and m 6A-modified RNA. YTHDF2-IN-1 induces cell cycle arrest and Apoptosis. YTHDF2-IN-1 is applicable to research on chronic myeloid leukemia, colon cancer and choriocarcinoma [1].
Cat. No.: HY-RS15935
Target:
Research Areas:
YTHDC1 Human Pre-designed siRNA Set A contains three designed siRNAs for YTHDC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS18431
Target:
Research Areas:
Ythdc1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ythdc1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-184495
PROTAC YTHDC1 Degrader-1 is a selective, CRBN-recruiting YTHDC1 PROTAC degrader with a DC50 of 11.42 nM. PROTAC YTHDC1 Degrader-1 induces ubiquitination and degradation of YTHDC1. PROTAC YTHDC1 Degrader-1 induces G1 phase arrest and inhibits cell cycle progression. PROTAC YTHDC1 Degrader-1 also induces Apoptosis. PROTAC YTHDC1 Degrader-1 exhibits anticancer activity against leukemia. PROTAC YTHDC1 Degrader-1 can be used for the research of acute myeloid leukemia [1].
Cat. No.: HY-RS24912
Target:
Research Areas:
Ythdc1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ythdc1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P87148
Synonyms: KIAA1966 antibody; Putative splicing factor YT521 antibody; splicing factor YT521-B antibody; YT521 antibody; YT521-B antibody; YTDC1_HUMAN antibody; YTH domain-containing protein 1 antibody; YTHDC1 antibody;
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
